4/16
10:13 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
4/16
10:13 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
4/16
09:25 am
halo
Rating for HALO
Low
Report
Rating for HALO
4/16
09:25 am
halo
Rating for HALO
Low
Report
Rating for HALO
2/21
12:19 pm
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $72.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $72.00 price target on the stock.
2/21
12:19 pm
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $72.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $72.00 price target on the stock.
2/21
12:08 pm
halo
Rating for HALO
Low
Report
Rating for HALO
2/21
12:08 pm
halo
Rating for HALO
Low
Report
Rating for HALO